Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 89050126 | 8905012 | 6 | F | 2003 | 20160706 | 20121109 | 20160714 | EXP | US-ASTRAZENECA-2012SE83911 | ASTRAZENECA | 70.00 | YR | F | Y | 61.20000 | KG | 20160714 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 89050126 | 8905012 | 1 | PS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | U | U | 21153 | 40 | MG | CAPSULE | QD | |||||
| 89050126 | 8905012 | 2 | SS | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | U | U | 0 | 20 | MG | TABLET | QD | |||||
| 89050126 | 8905012 | 3 | C | TYLENOL | ACETAMINOPHEN | 1 | Oral | TAKE 650 MG BY MOUTH EVERY 6 HRS AS NEEDED | 0 | TABLET | |||||||||
| 89050126 | 8905012 | 4 | C | NORVASC | AMLODIPINE BESYLATE | 1 | Oral | 0 | 10 | MG | TABLET | QD | |||||||
| 89050126 | 8905012 | 5 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 0 | 325 | MG | TABLET | QD | |||||||
| 89050126 | 8905012 | 6 | C | VALIUM | DIAZEPAM | 1 | Oral | 5 MG, TWO TIMES A DAY AS NEEDED | 0 | TABLET | |||||||||
| 89050126 | 8905012 | 7 | C | ADVAIR HFA | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | Respiratory (inhalation) | 250/50 MCG/DOSE, 1 PUFF, EVERY 12 HRS | 0 | ||||||||||
| 89050126 | 8905012 | 8 | C | LASIX | FUROSEMIDE | 1 | Oral | 0 | 40 | MG | TABLET | QD | |||||||
| 89050126 | 8905012 | 9 | C | DUO-NEB | 2 | 0.5 MG/3MG(2.5MG BASE)/3ML, TAKE 3 ML BY NEBULIZATION, EVERY 6 HRS AS ANEEDED | 0 | ||||||||||||
| 89050126 | 8905012 | 10 | C | COZAAR | LOSARTAN POTASSIUM | 1 | Oral | 0 | 50 | MG | TABLET | BID | |||||||
| 89050126 | 8905012 | 11 | C | COZAAR | LOSARTAN POTASSIUM | 1 | Oral | 0 | 50 | MG | TABLET | BID | |||||||
| 89050126 | 8905012 | 12 | C | LOPRESSOR | METOPROLOL TARTRATE | 1 | Oral | 0 | 12.5 | MG | TABLET | BID | |||||||
| 89050126 | 8905012 | 13 | C | NASONEX | MOMETASONE FUROATE | 1 | Nasal | 2 SPRAY DAILY | 0 | ||||||||||
| 89050126 | 8905012 | 14 | C | MULTIVITAMIN | VITAMINS | 1 | Oral | DAILY | 0 | ||||||||||
| 89050126 | 8905012 | 15 | C | MIRALAX | POLYETHYLENE GLYCOL 3350 | 1 | Oral | 17.0G AS REQUIRED | 0 | 17 | G | ||||||||
| 89050126 | 8905012 | 16 | C | LIPITOR | ATORVASTATIN CALCIUM | 1 | 0 | ||||||||||||
| 89050126 | 8905012 | 17 | C | ACIDOPHILUS | LACTOBACILLUS ACIDOPHILUS | 1 | Oral | 0 | 175 | MG | QD | ||||||||
| 89050126 | 8905012 | 18 | C | METOPROLOL TARTRATE. | METOPROLOL TARTRATE | 1 | Oral | 0 | 25 | MG | Q12H | ||||||||
| 89050126 | 8905012 | 19 | C | PETROPROZOL | 2 | Oral | 0 | 40 | MG | QD | |||||||||
| 89050126 | 8905012 | 20 | C | MONTELUKAST | MONTELUKAST SODIUM | 1 | Respiratory (inhalation) | 0 | 10 | MG | QD | ||||||||
| 89050126 | 8905012 | 21 | C | DIAZEPAM. | DIAZEPAM | 1 | Oral | 0 | |||||||||||
| 89050126 | 8905012 | 22 | C | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | 0 | 40 | MG | QD | ||||||||
| 89050126 | 8905012 | 23 | C | CENTRUM SILVER | MINERALSVITAMINS | 1 | Oral | 0 | |||||||||||
| 89050126 | 8905012 | 24 | C | IPRATROPIUM BROMIDE. | IPRATROPIUM BROMIDE | 1 | Respiratory (inhalation) | 0.5MG UNKNOWN | 0 | .5 | MG | ||||||||
| 89050126 | 8905012 | 25 | C | ABUTEROL | 2 | Respiratory (inhalation) | 3.0MG UNKNOWN | 0 | 3 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 89050126 | 8905012 | 1 | Abdominal discomfort |
| 89050126 | 8905012 | 2 | Coronary artery occlusion |
| 89050126 | 8905012 | 5 | Cardiac disorder |
| 89050126 | 8905012 | 7 | Lung disorder |
| 89050126 | 8905012 | 8 | Fluid retention |
| 89050126 | 8905012 | 10 | Blood potassium abnormal |
| 89050126 | 8905012 | 11 | Blood pressure abnormal |
| 89050126 | 8905012 | 17 | Abdominal discomfort |
| 89050126 | 8905012 | 18 | Cardiac disorder |
| 89050126 | 8905012 | 20 | Hypersensitivity |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 89050126 | 8905012 | HO |
| 89050126 | 8905012 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 89050126 | 8905012 | Body height decreased | |
| 89050126 | 8905012 | Bronchitis | |
| 89050126 | 8905012 | Chronic obstructive pulmonary disease | |
| 89050126 | 8905012 | Depression | |
| 89050126 | 8905012 | Drug dose omission | |
| 89050126 | 8905012 | Dyspnoea | |
| 89050126 | 8905012 | Lung neoplasm malignant | |
| 89050126 | 8905012 | Malaise | |
| 89050126 | 8905012 | Myocardial infarction | |
| 89050126 | 8905012 | Pain | |
| 89050126 | 8905012 | Pneumonia bacterial | |
| 89050126 | 8905012 | Sinus disorder | |
| 89050126 | 8905012 | Upper-airway cough syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 89050126 | 8905012 | 17 | 2014 | 0 |